Nestlé Health Science plots next steps for C. diff drug Vowst after robust uptake
After a better-than-expected launch, Nestlé Health Science is planning its next commercialization moves for Vowst, an oral pill to treat recurring Clostridioides difficile, or C. diff, infections.
The first-of-its-kind treatment, based on bacterial spores purified from human stool, was approved in April and launched in June. Since then, Vowst has been prescribed by more than 2,000 doctors with more than 3,000 patients now on therapy, said Moreno Perugini, president of active and medical nutrition and pharmaceutical therapies at Nestlé Health Science.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
